Why is Heineken worried that weight-loss drugs could hurt beer sales?

Heineken has warned that the growing use of weight-loss drugs could threaten beer and cider sales, urging British pubs and bars to adapt their offerings as consumers change their drinking habits.

A company presentation shared with hospitality customers this month and reviewed by Reuters shows that the world’s second-largest brewer is concerned about the impact of glucagon-like peptide-1 (GLP-1) medications on alcohol consumption. The drugs, including Novo Nordisk’s Ozempic and Wegovy, can reduce appetite and the desire to drink.

Heineken warned that the medicines could put pressure on beer and cider sales as users experience greater feelings of fullness and consume fewer drinks per occasion. It also cautioned that traditional outings involving multiple pints could become harder to sustain.

The presentation recommended that pubs and bars promote half-pints, low- and no-alcohol drinks, and food pairings such as small plates to retain customers and spending as GLP-1 use becomes more widespread in Britain.

The warning marks a rare acknowledgement by a major alcohol producer that weight-loss medications could pose a challenge to the industry’s sales.

How are weight-loss drugs changing alcohol consumption?

GLP-1 medications have gained popularity for their role in managing diabetes and obesity. Their effects on appetite and cravings are increasingly drawing attention across consumer industries, from food and beverages to clothing.

More from Business

Around 10 million people in the US used medications such as Ozempic and Wegovy last year, according to JPMorgan research cited by Reuters.

Emerging consumer spending data suggests that the medicines could also be changing purchasing patterns in the alcohol industry.

Research by market intelligence firm Circana, which tracked US households between 2024 and 2026, found that households with at least one GLP-1 user reduced spending on alcohol consumed both at home and outside. After two years on the medications, these households spent about 7 per cent less per month on alcohol than households without a user. Spending on beer was around 13.5 per cent lower.

Surveys conducted in Europe and the UK by Circana, NIQ and hospitality researcher KAM have also indicated that GLP-1 users are drinking less.

Of the 11 GLP-1 users interviewed by Reuters, 10 said they had reduced their alcohol consumption. Some reported discomfort, feeling unwell or experiencing prolonged hangovers, while others said they had simply lost the desire to drink.

Why is this a concern for Heineken?

The warning comes as alcohol companies face pressure from consumers cutting back on drinking for health and financial reasons. Lower consumption among GLP-1 users could add to those challenges, particularly in markets where beer sales are already struggling to grow.

Europe is Heineken’s largest market by revenue, while Britain has been a relative bright spot for the Dutch brewer. The company owns more than 2,000 pubs in the UK.

Beer generated nearly £14 billion in sales at British pubs, bars and restaurants in the year to February 2026, according to a Heineken UK report. Less than £300 million of that total came from no- and low-alcohol beers, highlighting the scale of the traditional beer market.

A sustained shift towards smaller servings or lower-alcohol alternatives could therefore have implications for pubs, bars and brewers that depend on consumers ordering multiple drinks during a visit.

Heineken said its presentation was part of its regular engagement with British hospitality businesses to help them understand changing market conditions.

The company told Reuters it had observed changes in consumption behaviour among GLP-1 users and would continue monitoring these trends in 2027.

It added that users were not necessarily giving up alcohol altogether but were increasingly choosing smaller servings, lower-alcohol drinks and more premium products. Heineken said its portfolio was well positioned to respond to these preferences.

Are other alcohol companies worried about GLP-1 drugs?

The wider alcohol industry has generally played down the potential impact of weight-loss medications, although companies are monitoring their growing popularity.

Diageo, the world’s largest spirits maker, has told investors that any impact from GLP-1 drugs should be manageable, even if their use becomes more widespread.

Carlsberg told Reuters that existing data did not yet support the conclusion that the medications were a clear driver of beer consumption trends. Anheuser-Busch InBev declined to comment.

However, emerging scientific research suggests that the drugs could affect alcohol consumption beyond their impact on appetite.

Joseph Schacht, a professor at the University of Colorado Anschutz, said GLP-1 medications may influence the brain’s reward pathways and reduce the motivation to drink. Schacht led a randomised controlled trial examining the effects of GLP-1 drugs on people with alcohol use disorder.

He said trials had consistently shown reductions in cravings and alcohol consumption among people with the disorder. Schacht described the potential as a “Prozac moment” for alcohol use disorder treatment while warning that broader reductions in drinking could create challenges for alcohol producers.

What does this mean for the beer industry?

The long-term impact remains uncertain, but the emerging evidence presents a potential challenge for an industry already navigating changing consumer preferences.

If GLP-1 medications continue to gain popularity and users consistently consume less alcohol, brewers and hospitality businesses may need to adapt their strategies around serving sizes, product portfolios and drinking occasions.

For Heineken, the immediate priority appears to be helping pubs and bars respond to these changing habits before they translate into sustained declines in customer visits and spending.

The broader question for the alcohol industry is whether weight-loss drugs will remain a niche factor in consumer behaviour or become a significant force reshaping beer demand.